Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
SAN DIEGO, Feb. 20, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CrownBio, a leader in the field of preclinical immuno-oncology research, offers a CAR T-cell platform for proof-of-concept and therapeutic efficacy validation. Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents. The addition of bioluminescence imaging (BLI) for non-invasive evaluation of systemic and orthotopic tumor progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
“We are committed to delivering innovative services to help our clients’ develop improved cancer therapeutics,” said Dr. Rajendra Kumari, CrownBio’s Chief Scientific Officer, UK. “Our non-invasive BLI capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents.”
Learn more about CrownBio’s CAR T-cell evaluation platform at https://www.crownbio.com/oncology/immuno-oncology/car-t-cell-therapy-models/
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
